KalVista Pharmaceuticals Statistics
Share Statistics
KalVista Pharmaceuticals has 49.72M
shares outstanding. The number of shares has increased by 17.84%
in one year.
| Shares Outstanding | 49.72M |
| Shares Change (YoY) | 17.84% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 11,301 |
| FTD / Avg. Volume | 1.88% |
Short Selling Information
The latest short interest is 5.86M, so 11.8% of the outstanding
shares have been sold short.
| Short Interest | 5.86M |
| Short % of Shares Out | 11.8% |
| Short % of Float | 13.32% |
| Short Ratio (days to cover) | 12.26 |
Valuation Ratios
The PE ratio is -3.3 and the forward
PE ratio is -3.87.
KalVista Pharmaceuticals's PEG ratio is
-0.12.
| PE Ratio | -3.3 |
| Forward PE | -3.87 |
| PS Ratio | 0 |
| Forward PS | 1.5 |
| PB Ratio | 2.02 |
| P/FCF Ratio | -4.66 |
| PEG Ratio | -0.12 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for KalVista Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.9,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.9 |
| Quick Ratio | 9.9 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-844,293.33 |
| Employee Count | 150 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -8.45M |
| Effective Tax Rate | 6.26% |
Stock Price Statistics
The stock price has increased by 1.5% in the
last 52 weeks. The beta is 0.05, so KalVista Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.05 |
| 52-Week Price Change | 1.5% |
| 50-Day Moving Average | 12.04 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 42.51 |
| Average Volume (20 Days) | 601,809 |
Income Statement
| Revenue | n/a |
| Gross Profit | -86.17M |
| Operating Income | -140.44M |
| Net Income | -126.64M |
| EBITDA | -134.28M |
| EBIT | -135.1M |
| Earnings Per Share (EPS) | -3.44 |
Full Income StatementBalance Sheet
The company has 31.79M in cash and 7.32M in
debt, giving a net cash position of 24.47M.
| Cash & Cash Equivalents | 31.79M |
| Total Debt | 7.32M |
| Net Cash | 24.47M |
| Retained Earnings | -469.73M |
| Total Assets | 275.99M |
| Working Capital | 241.74M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -89.23M
and capital expenditures -443K, giving a free cash flow of -89.67M.
| Operating Cash Flow | -89.23M |
| Capital Expenditures | -443K |
| Free Cash Flow | -89.67M |
| FCF Per Share | -2.44 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
